---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-231951"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:56:45.902522+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Veru reports Phase 3 ARTEST data: enobosarm monotherapy shows 12.5% ORR vs 0% control in metastatic breast cancer

## Summary
- Enobosarm monotherapy achieved 2 PR/16 (12.5%) ORR vs 0 PR/18 for active control in discontinued Phase 3 ARTEST trial.
- In patients with ≤3 prior endocrine therapies and ≤1 prior CDK4/6 inhibitor, ORR was 33.3% (2/6) vs 0% control.
- Enobosarm was well tolerated with no masculinizing AEs or hematocrit increases.
- Trial discontinued to focus on earlier-line ENABLAR-2 Phase 3 study of enobosarm + abemaciclib.

## SEC filing metadata
- accession: 0001193125-23-231951
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312523231951/0001193125-23-231951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312523231951/d505806d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-231951
- JSON: https://secwatch.observer/filing/0001193125-23-231951.json
- Plain text: https://secwatch.observer/filing/0001193125-23-231951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.